Enovis ENOV Contingent consideration fair value adjustments

Contingent consideration fair value adjustments at other companies

ArtivionAORT

——

Globus MedicalGMED

——

CONMEDCNMD

——

Merit Medical SystemsMMSI

——

IAR

Integra LifeSciencesIART

——

Other financials

Income statement

See full

Revenue$589.2M+5.4%

Gross profit$365.5M+10.0%

Operating income$6.5M+114%

Net income-$8.8M+84.3%

EPS (diluted)-$0.15+84.7%

Balance sheet

See full

Cash & equivalents$33.1M-13.9%

Total debt$1.4B-3.1%

Total equity$1.5B-43.6%

Total assets$3.8B-21.4%

Cash flow

See full

Operating cash flow$24.0M+1,601%

CapEx$52.8M+22.1%

Free cash flow-$28.9M+35.7%

Valuation

See full

Market cap$1.23B-28.4%

Enterprise value$2.55B-17.1%

P/S0.5×-0.3×

Profitability

See full

Gross margin60.5%+4.0pp

Operating margin-47%+18.6pp

Net margin-49.9%+24.1pp

FCF margin-3.1%-1.1pp

Returns & leverage

See full

Return on equity-55.5%-1,722pp

Debt / equity0.9×+0.4×

Current ratio2×-0.5×

Where this comes from

Reported directly by Enovis in its filing.

Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.

The official record: Enovis’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Enovis's contingent consideration fair value adjustments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Enovis's contingent consideration fair value adjustments?: Enovis (ENOV) reported contingent consideration fair value adjustments of $0 in Q1 2026.
How has Enovis's contingent consideration fair value adjustments changed year-over-year?: Enovis's contingent consideration fair value adjustments decreased by 100.0% year-over-year, from $1.79M to $0.